Theravance Biopharma Return on Assets (ROA) Growth & History (TBPH)

Theravance Biopharma's return on assets (roa) was 25.22% for fiscal 2025.

View full Theravance Biopharma company overview

Theravance Biopharma annual return on assets (roa) history

Theravance Biopharma annual return on assets (roa)

Fiscal yearPeriod endedReturn on assets (ROA)Change (percentage points)
20252025-12-3125.22%+40.55 pp
20242024-12-31−15.33%−4.17 pp
20232023-12-31−11.16%−188.74 pp
20222022-12-31177.58%+224.85 pp
20212021-12-31−47.26%+16.07 pp
20202020-12-31−63.34%−14.54 pp
20192019-12-31−48.80%−5.77 pp
20182018-12-31−43.03%+9.79 pp
20172017-12-31−52.82%−12.23 pp
20162016-12-31−40.60%+16.54 pp
20152015-12-31−57.13%+73.49 pp
20142014-12-31−130.62%

Theravance Biopharma return on assets (roa) trends

Over the last five fiscal years, Theravance Biopharma's return on assets (roa) increased from −63.34% to 25.22%, a change of +88.56 percentage points. The latest reported quarter, Q2 2026, shows 12.01%.

About the metric

What return on assets means

Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.

Calculation and source

How return on assets is calculated

TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Theravance Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about TBPH yet. Start the conversation.

Write the first post